4. HIV infection is caused by a retrovirus that
infects and replicates in human lymphocytes
and macrophages, eroding the integrity of the
human immune system over a number of
years, culminating in immune deficiency and a
susceptibility to a series of opportunistic and
other infections as well as the development of
certain malignancies.
5. Epidemiology
02
Approximately 84 million people have become infected with HIV
and 40 million people have died of AIDS-related illness since the
start of the epidemic. New cases peaked in 1999 (3.16 million)
and have gradually decreased since then.
7. Aetiology
The human immunodeficiency retroviruses can be broadly divided
into two groups: HIV-1 and HIV-2, both of which cause AIDS.
Infection with HIV-1 is associated with a progressive decrease in CD4
T-cell count and an increase in viral load leading to clinical AIDS. The
stage of infection can be determined by measuring the patient's CD4
T-cell count and correlating clinical findings, such as AIDS-defining
illnesses. HIV-2 infection has a more indolent course and is largely
limited to West Africa. Within the main types of HIV viruses there are
many genetically distinct subgroups as the virus mutates and
changes over time.
10. Classification
•HIV type 1 (HIV 1) is the virus responsible for the global epidemic.
•HIV type 2 (HIV 2) is less pathogenic and restricted in the most part to
West Africa.
11. Diagnosis
1. History and exam
Pressnce of risk factors
Fever and night sweats
Weight loss
Skin rashes and post-inflammatory scars
Oral ulcers, angular cheilitis, oral thrush, oral leukoplakia
diarrhoea
Risk factors
People who inject drugs
Gay men and other men
who have sex with men
Commercial
sex worker
Transgender women
Unprotected receptive anal
intercourse
18. Criteria
CDC surveilllance case definition HIV infection stage based on age-specific CD4+ T-lymphocyte count or
CD4+ T lymphocyte percentage of total lymphocytes
20. Treatment
Treatment does not have to be delayed while awaiting results of
resistance testing. While awaiting results of resistance testing, we
suggest one of the following regimens
• Dolutegravir plus tenofovir and either emtricitabine or lamivudine
• Bictegravir-tenofovir alafenamide-emtricitabine
• Ritonavir-boosted darunavir plus tenofovir and
either emtricitabine or lamivudine.
21. Complication
Acute seroconversion
Severe acute syndrome
Rapid progressors
AIDS
Immune suppression pre-AIDS
HIV related oppotunistic infections